In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the May issue of the Journal of Thoracic Oncology. Dr. Bonnie Ky, Founder’s Professor of Cardio-Oncology at the Perelman School of Medicine, University of Pennsylvania, discusses their article “Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer”; and Dr. David Planchard, Head of Thoracic Group at Gustave Roussy, discusses their article “Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.”

Guests:

Bonnie Ky, MD, MSCE

Founders Professor of Cardio-Oncology, Division of Cardiovascular Medicine

Senior Scholar, Center for Clinical Epidemiology and Biostatistics

Director, Thalheimer Center for Cardio-Oncology,

Director, Penn Center for Quantitative Echocardiography

Perelman School of Medicine at the University of Pennsylvania, United States.

Dr. David Planchard is a thoracic oncologist and head of Thoracic Group at Gustave Roussy, where he is responsible for coordinating the care of patients with lung cancer, pleural mesothelioma and thymic tumors. He is also Chairman of the International Centre for Thoracic Cancers (CICT), a health cooperation consortium involving Gustave Roussy, Hôpital Marie-Lannelongue and Hôpital Paris Saint-Joseph.

Recommended Reading:

Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer: https://www.jto.org/article/S1556-0864(26)00002-X/fulltext

Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial: https://www.jto.org/article/S1556-0864(25)03021-7/fulltext

JTO May 2026 Issue: https://www.jto.org/issue/S1556-0864(26)X2003-2